Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.
Wieczorek A, Stefanowicz J, Hennig M, Adamkiewicz-Drozynska E, Stypinska M, Dembowska-Baginska B, Gamrot Z, Woszczyk M, Geisler J, Szczepanski T, Skoczen S, Ussowicz M, Pogorzala M, Janczar S, Balwierz W.
BMC Cancer. 2022 Jun 25;22(1):701. doi: 10.1186/s12885-022-09776-x.
PMID:35752779
Biological and Genetic Features of Neuroblastoma and Their Clinical Importance.
Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging.
Kellie SJ, Hayes FA, Bowman L, Kovnar EH, Langston J, Jenkins JJ 3rd, Pao WJ, Ducos R, Green AA.
Cancer. 1991 Nov 1;68(9):1999-2006. doi: 10.1002/1097-0142(19911101)68:9<1999::aid-cncr2820680926>3.0.co;2-0.
PMID:1913549
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
Chan GC, Chan CM.
Biomolecules. 2022 Feb 24;12(3):358. doi: 10.3390/biom12030358.
PMID:35327550
Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review.
Kramer K, Kushner B, Heller G, Cheung NK.
Cancer. 2001 Apr 15;91(8):1510-9.
PMID:11301399
FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.
Jessa S, De Cola A, Chandarana B, McNicholas M, Hébert S, Ptack A, Faury D, Tsai JW, Korshunov A, Phoenix TN, Ellezam B, Jones DTW, Taylor MD, Bandopadhayay P, Pathania M, Jabado N, Kleinman CL.
Cancer Res. 2025 Jan 15;85(2):231-250. doi: 10.1158/0008-5472.CAN-24-2248.